ProB-type natriuretic peptide-1-108 processing and degradation in human heart failure

Circulation: Heart Failure

Volumn 8, Issue 1, 2015, Pages 89-97

  Huntley, Brenda K ^a   Sandberg, Sharon M ^a   Heublein, Denise M ^a   Jeson Sangaralingham, S ^a   Burnett, John C ^a   Ichiki, Tomoko ^a  

^a MAYO CLINIC   (United States)

Author keywords

B type natriuretic peptide; Enzymes; Heart failure

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE 1 32; CYCLIC GMP; DIPEPTIDYL PEPTIDASE IV; GUANYLATE CYCLASE; HISTIDINE; PRO B TYPE NATRIURETIC PEPTIDE 1 108; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; PRO-BNP1-108;

AGED; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DENSITOMETRY; EX VIVO STUDY; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PROCESSING; CARDIAC MUSCLE CELL; CELL CULTURE; COMPARATIVE STUDY; HEART VENTRICLE REMODELING; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; WESTERN BLOTTING;

AGED; BIOMARKERS; BLOTTING, WESTERN; CELLS, CULTURED; FEMALE; HEART FAILURE; HUMANS; MALE; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDE, BRAIN; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84927713108     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.114.001174     Document Type: Article

References (36)

1. van den Akker F. Structural insights into the ligand binding domains of membrane bound guanylyl cyclases and natriuretic peptide receptors. J Mol Biol. 2001;311:923-937.
2. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature. 1988;332:78-81.
3. Yan W, Wu F, Morser J, Wu Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci U S A. 2000;97:8525-8529.
4. Semenov AG, Tamm NN, Seferian KR, Postnikov AB, Karpova NS, Serebryanaya DV, Koshkina EV, Krasnoselsky MI, Katrukha AG. Processing of pro-B-type natriuretic peptide: furin and corin as candidate convertases. Clin Chem. 2010;56:1166-1176.
5. Brandt I, Lambeir AM, Ketelslegers JM, Vanderheyden M, Scharpé S, De Meester I. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem. 2006;52:82-87.
6. Boerrigter G, Costello-Boerrigter LC, Harty GJ, Lapp H, Burnett JC Jr. Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am J Physiol Regul Integr Comp Physiol. 2007;292:R897-R901.
7. Pankow K, Wang Y, Gembardt F, Krause E, Sun X, Krause G, Schultheiss HP, Siems WE, Walther T. Successive action of meprin A and neprilysin catabolizes B-type natriuretic peptide. Circ Res. 2007;101:875-882.
8. Ralat LA, Guo Q, Ren M, Funke T, Dickey DM, Potter LR, Tang WJ. Insulin-degrading enzyme modulates the natriuretic peptide-mediated signaling response. J Biol Chem. 2011;286:4670-4679.
9. Toll L, Brandt SR, Olsen CM, Judd AK, Almquist RG. Isolation and characterization of a new atrial peptide-degrading enzyme from bovine kidney. Biochem Biophys Res Commun. 1991;175:886-893.
10. Müller D, Schulze C, Baumeister H, Buck F, Richter D. Rat insulindegrading enzyme: cleavage pattern of the natriuretic peptide hormones ANP, BNP, and CNP revealed by HPLC and mass spectrometry. Biochemistry. 1992;31:11138-11143.
11. Heublein DM, Huntley BK, Boerrigter G, Cataliotti A, Sandberg SM, Redfield MM, Burnett JC Jr. Immunoreactivity and guanosine 3',5'-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension. 2007;49:1114-1119.
12. Ichiki T, Huntley BK, Burnett JC Jr. BNP molecular forms and processing by the cardiac serine protease corin. Adv Clin Chem. 2013;61:1-31.
13. Hawkridge AM, Heublein DM, Bergen HR III, Cataliotti A, Burnett JC Jr, Muddiman DC. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A. 2005;102:17442-17447.
14. Liang F, O'Rear J, Schellenberger U, Tai L, Lasecki M, Schreiner GF, Apple FS, Maisel AS, Pollitt NS, Protter AA. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol. 2007;49:1071-1078.
15. Andrews GL, Shuford CM, Burnett JC Jr, Hawkridge AM, Muddiman DC. Coupling of a vented column with splitless nanoRPLC-ESI-MS for the improved separation and detection of brain natriuretic peptide-32 and its proteolytic peptides. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:948-954.
16. Miller WL, Phelps MA, Wood CM, Schellenberger U, Van Le A, Perichon R, Jaffe AS. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. Circ Heart Fail. 2011;4:355-360.
17. Ichiki T, Huntley BK, Heublein DM, Sandberg SM, McKie PM, Martin FL, Jougasaki M, Burnett JC Jr. Corin is present in the normal human heart, kidney, and blood, with pro-B-type natriuretic peptide processing in the circulation. Clin Chem. 2011;57:40-47.
18. Macheret F, Boerrigter G, McKie PM, Costello-Boerrigter LC, Lahr BD, Heublein DM, Sandberg SM, Ikeda Y, Cataliotti A, Bailey KR, Rodeheffer RJ, Burnett JC, Jr. Pro-b-type natriuretic peptide1-108 circulates in the general community: Plasma determinants and detection of left ventricular systolic dysfunction. J Am Coll Cardiol. 2010;57:1386-1395.
19. Steen H, Mann M. The ABC's (and XYZ's) of peptide sequencing. Nat Rev Mol Cell Biol. 2004;5:699-711.
20. Miller WL, Burnett JC Jr, Hartman KA, Hodge DO, Giuliani I, Minard F, Larue C, Jaffe AS. Role for precursor Pro-B type natriuretic peptide in assessing response to therapy and prognosis in patients with decompensated heart failure treated with nesiritide. Clin Chim Acta. 2009;406:119-123.
21. Burnett JC Jr, Kao PC, Hu DC, Heser DW, Heublein D, Granger JP, Opgenorth TJ, Reeder GS. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science. 1986;231:1145-1147.
22. Macheret F, Boerrigter G, McKie P, Costello-Boerrigter L, Lahr B, Heublein D, Sandberg S, Ikeda Y, Cataliotti A, Bailey K, Rodeheffer R, Burnett JC Jr. Pro-B-type natriuretic peptide(1-108) circulates in the general community: plasma determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2011;57:1386-1395.
23. Costello-Boerrigter LC, Lapp H, Boerrigter G, Lerman A, Bufe A, Macheret F, Heublein DM, Larue C, Burnett JC Jr. Secretion of prohormone of B-type natriuretic peptide, proBNP1-108, is increased in heart failure. JACC Heart Fail. 2013;1:207-212.
24. Martin FL, Sangaralingham SJ, Huntley BK, McKie PM, Ichiki T, Chen HH, Korinek J, Harders GE, Burnett JC Jr. CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart. PLoS One. 2012;7:e52422.
25. Huntley BK, Ichiki T, Sangaralingham SJ, Chen HH, Burnett JC Jr. B-type natriuretic peptide and extracellular matrix protein interactions in human cardiac fibroblasts. J Cell Physiol. 2010;225:251-255.
26. Jiang J, Wu S, Wang W, Chen S, Peng J, Zhang X, Wu Q. Ectodomain shedding and autocleavage of the cardiac membrane protease corin. J Biol Chem. 2011;286:10066-10072.
27. Seferian KR, Tamm NN, Semenov AG, Mukharyamova KS, Tolstaya AA, Koshkina EV, Kara AN, Krasnoselsky MI, Apple FS, Esakova TV, Filatov VL, Katrukha AG. The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. Clin Chem. 2007;53:866-873.
28. Dickey DM, Potter LR. ProBNP(1-108) is resistant to degradation and activates guanylyl cyclase-A with reduced potency. Clin Chem. 2011;57:1272-1278.
29. Vanderheyden M, Bartunek J, Goethals M, Verstreken S, Lambeir AM, De Meester I, Scharpé S. Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside. Clin Chem Lab Med. 2009;47:248-252.
30. Rame JE, Tam SW, McNamara D, Worcel M, Sabolinski ML, Wu AH, Dries DL. Dysfunctional corin i555(p568) allele is associated with impaired brain natriuretic peptide processing and adverse outcomes in blacks with systolic heart failure: results from the Genetic Risk Assessment in Heart Failure substudy. Circ Heart Fail. 2009;2:541-548.
31. Ibebuogu UN, Gladysheva IP, Houng AK, Reed GL. Decompensated heart failure is associated with reduced corin levels and decreased cleavage of pro-atrial natriuretic peptide. Circ Heart Fail. 2011;4:114-120.
32. Dong N, Chen S, Yang J, He L, Liu P, Zheng D, Li L, Zhou Y, Ruan C, Plow E, Wu Q. Plasma soluble corin in patients with heart failure. Circ Heart Fail. 2010;3:207-211.
33. Peng J, Jiang J, Wang W, Qi X, Sun XL, Wu Q. Glycosylation and processing of pro-B-type natriuretic peptide in cardiomyocytes. Biochem Biophys Res Commun. 2011;411:593-598.
34. dos Santos L, Salles TA, Arruda-Junior DF, Campos LC, Pereira AC, Barreto AL, Antonio EL, Mansur AJ, Tucci PJ, Krieger JE, Girardi AC. Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure. Circ Heart Fail. 2013;6:1029-1038.
35. Komajda M, Lam CS. Heart failure with preserved ejection fraction: a clinical dilemma. Eur Heart J. 2014;35:1022-1032.
36. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ; Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387-1395.